Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?

Area of Science:

• Nuclear Medicine
• Radiation Oncology
• Urologic Oncology

Background:

• Limited randomized trials exist for PSMA-PET guided post-prostatectomy radiotherapy.
• Key questions involve dose escalation for PSMA-PET positive lesions and dose reduction for negative scans.

Purpose of the Study:

• To review and discuss current evidence on PSMA-PET's role in radiotherapy planning after prostatectomy.
• To evaluate the efficacy of dose adjustments based on PSMA-PET findings.

Main Methods:

• Literature review and synthesis of available evidence on PSMA-PET in post-prostatectomy radiotherapy.
• Analysis of studies addressing dose escalation and reduction strategies.

Main Results:

• Evidence suggests a potential advantage for dose escalation in PSMA-PET positive cases, though not consistently shown.
• Retrospective data indicate conventional doses may suffice for PSMA-PET positive lesions.
• No current evidence supports dose reduction when PSMA-PET scans are negative.

Conclusions:

• PSMA-PET guided radiotherapy shows promise, particularly for dose escalation, but requires further validation.
• Future research should integrate PSMA-PET with genomic data for personalized treatment decisions.
• Development of intra-individual references is crucial for identifying aggressive lesions.